{"schema":"sb.node.v1","id":"sb:e/4cc9a5ce4bc57e4a41e18ce9","kind":"entity","label":{"text":"ultragenyx","locale":"en"},"identity":{"anchor":"label:en:ultragenyx","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-09T15:59:00.704884+00:00","snapshot":"deploy 5502f48ed36537591703f5d6fb62f67c25fbf5e1"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":24,"separatePublishers":16,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim"},"admission":{"state":"provisional","reason":"entity graph provenance 'observed'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-08-11","to":"2026-10-08","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.458: about 54% of mentions carry no typed assertion"]}},"dimensions":{"domains":["biotech_pharma","auto","fda_decisions","rare_diseases"],"activeDays":13,"assertions":{"regulatory-approval":9,"launch-release":1,"utterance":1}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":11,"byKind":{"observation":11},"withheld":{"state":"withheld","count":1,"reason":"1 receipt withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/73e01f206479bb60aa35a3da","kind":"observation","label":"AllSci News · 2026-10-08 · Ultragenyx to sell FDA priority review voucher for USD 210 million","url":"https://allsci.com/news/biotech/priority-review-voucher-ultragenyx-agrees-to-sell/"},{"id":"sb:o/37a695e8a65b4e6cd164bf69","kind":"observation","label":"Endpoints News · 2026-10-07 · Ultragenyx sells PRV for $210M and still has another to monetize","url":"https://endpoints.news/ultragenyx-sells-prv-for-210m-and-still-has-another-to-monetize/"},{"id":"sb:o/448b7e070aaf467a2ad0908b","kind":"observation","label":"MarketBeat News Feed · 2026-09-26 · Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Consensus Price Target of $34.58 According to Analysts","url":"https://www.marketbeat.com/instant-alerts/consensus-ultragenyx-pharmaceutical-inc-nasdaq-rare-stock-has-consensus-price-target-of-3458-according-to-analysts-2026-09-26/"},{"id":"sb:o/e3e8a5158d3ab4801ac7bb29","kind":"observation","label":"BioPharma Dive · 2026-09-19 · Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug","url":"https://www.biopharmadive.com/news/ultragenyx-fayuvi-orum-bristol-lunsumio-longeveron-rocket-danon/830512/"},{"id":"sb:o/4ec0bcdc14ea55ca7dd5c5eb","kind":"observation","label":"Endpoints News · 2026-09-19 · FDA approves Ultragenyx's gene therapy for Sanfilippo syndrome type A","url":"https://endpoints.news/fda-approves-ultragenyxs-gene-therapy-for-sanfilippo-syndrome-type-a/"},{"id":"sb:o/5837a91bff6440d1c65d1e7d","kind":"observation","label":"Fierce Pharma · 2026-09-18 · FDA approves Ultragenyx’s gene therapy Fayuvi for rare neurodegenerative disorder","url":"https://www.fiercepharma.com/pharma/fda-approves-ultragenyx-gene-therapy-fayuvi-rare-neurodegenerative-disorder"},{"id":"sb:o/4903530c4c9c97d32e549e38","kind":"observation","label":"MarketBeat News Feed · 2026-09-18 · Cantor Fitzgerald Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock","url":"https://www.marketbeat.com/instant-alerts/analyst-cantor-fitzgerald-forecasts-strong-price-appreciation-for-ultragenyx-pharmaceutical-nasdaq-rare-stock-2026-09-18/"},{"id":"sb:o/6ea3935578fca97f9e64d231","kind":"observation","label":"MarketBeat News Feed · 2026-09-16 · Ultragenyx Pharmaceutical (NASDAQ:RARE) CAO Theodore Alan Huizenga Sells 1,283 Shares of Stock","url":"https://www.insidertrades.com/alerts/nasdaq-rare-insider-buying-and-selling-2026-09-16/"},{"id":"sb:o/d94780731db44fe3e8b81f03","kind":"observation","label":"STAT News · 2026-09-04 · STAT+: We’re reading about an Ultragenyx failure, RevMed for lung cancer, and more","url":"https://www.statnews.com/pharmalot/2026/09/03/pharmalittle-ultrangenyx-gene-therapy-failure-rev-med-lung-cancer/?utm_campaign=rss"},{"id":"sb:o/2cf0d145b1f48e60cf587395","kind":"observation","label":"STAT News · 2026-09-03 · STAT+: Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial","url":"https://www.statnews.com/2026/09/02/ultragenyx-drug-angelman-syndrome-clinical-trial/?utm_campaign=rss"}],"cursor":"c1.eyJpZCI6InNiOmUvNGNjOWE1Y2U0YmM1N2U0YTQxZTE4Y2U5IiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA5VDE1OjU5OjAwLjcwNDg4NCswMDowMCJ9","order":"newest first; we keep the 11 newest receipts for this entity. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":3,"byKind":{"co-mentioned":3},"items":[{"kind":"relation","label":"co-mentioned with gene therapy (14 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/1bb5f00b46fb117be8e77305"},{"kind":"relation","label":"co-mentioned with fda (13 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/b67c4b94bccc02b6f5f5dc50"},{"kind":"relation","label":"co-mentioned with sanfilippo (9 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/482ef44cb3be15fae7adf14b"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/4cc9a5ce4bc57e4a41e18ce9","mcp":"traverse {\"id\":\"sb:e/4cc9a5ce4bc57e4a41e18ce9\"}","page":"/entity/ultragenyx/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/4cc9a5ce4bc57e4a41e18ce9\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/4cc9a5ce4bc57e4a41e18ce9\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/4cc9a5ce4bc57e4a41e18ce9\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/4cc9a5ce4bc57e4a41e18ce9\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}